The Phase I Nerofe (dTCApFs) human trial summary has been published in the Molecular and Clinical Oncology Journal.
In this trial Nerofe was found to be safe and well‑tolerated, and potentially efficacious as an anti-cancer agent.
New Article Published: Nerofe Phase I trial summary
December 11, 2017Related Posts
-
Cooperation with Harvard Medical School (MGH)
October 27, 2019ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
-
Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd
April 9, 2019Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John […]
-
ISK attended the 2019 Sachs conference in Zurich
March 5, 2019 -
Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board
February 25, 2019 -
Nerofe has received a new US patent for metastatic cancer treatment
November 21, 2018
ISK attended the 2019 Sachs conference in Zurich
Nerofe Pre-clinical Paper Published in Molecular and Clinical Oncology Journal
